361 related articles for article (PubMed ID: 33139601)
1. Pancreatic Diseases and Microbiota: A Literature Review and Future Perspectives.
Gesualdo M; Rizzi F; Bonetto S; Rizza S; Cravero F; Saracco GM; De Angelis CG
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33139601
[TBL] [Abstract][Full Text] [Related]
2. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.
Distrutti E; Monaldi L; Ricci P; Fiorucci S
World J Gastroenterol; 2016 Feb; 22(7):2219-41. PubMed ID: 26900286
[TBL] [Abstract][Full Text] [Related]
3. The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy.
Cammarota G; Ianiro G; Cianci R; Bibbò S; Gasbarrini A; Currò D
Pharmacol Ther; 2015 May; 149():191-212. PubMed ID: 25561343
[TBL] [Abstract][Full Text] [Related]
4. Rebuilding the Gut Microbiota Ecosystem.
Gagliardi A; Totino V; Cacciotti F; Iebba V; Neroni B; Bonfiglio G; Trancassini M; Passariello C; Pantanella F; Schippa S
Int J Environ Res Public Health; 2018 Aug; 15(8):. PubMed ID: 30087270
[TBL] [Abstract][Full Text] [Related]
5. Gut Microbiota and Chronic Constipation: A Review and Update.
Ohkusa T; Koido S; Nishikawa Y; Sato N
Front Med (Lausanne); 2019; 6():19. PubMed ID: 30809523
[No Abstract] [Full Text] [Related]
6. Gut Dysbiosis in Pancreatic Diseases: A Causative Factor and a Novel Therapeutic Target.
Zhang T; Gao G; Sakandar HA; Kwok LY; Sun Z
Front Nutr; 2022; 9():814269. PubMed ID: 35242797
[TBL] [Abstract][Full Text] [Related]
7. Microbiota abnormalities in inflammatory airway diseases - Potential for therapy.
Gollwitzer ES; Marsland BJ
Pharmacol Ther; 2014 Jan; 141(1):32-9. PubMed ID: 23969226
[TBL] [Abstract][Full Text] [Related]
8. Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients.
Matijašić M; Meštrović T; Perić M; Čipčić Paljetak H; Panek M; Vranešić Bender D; Ljubas Kelečić D; Krznarić Ž; Verbanac D
Int J Mol Sci; 2016 Apr; 17(4):. PubMed ID: 27104515
[TBL] [Abstract][Full Text] [Related]
9. Alteration of the intestinal microbiota as a cause of and a potential therapeutic option in irritable bowel syndrome.
König J; Brummer RJ
Benef Microbes; 2014 Sep; 5(3):247-61. PubMed ID: 24583610
[TBL] [Abstract][Full Text] [Related]
10. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
[TBL] [Abstract][Full Text] [Related]
11. Organ transplantation and gut microbiota: current reviews and future challenges.
Xiao J; Peng Z; Liao Y; Sun H; Chen W; Chen X; Wei Z; Yang C; Nüssler AK; Liu J; Yang W
Am J Transl Res; 2018; 10(11):3330-3344. PubMed ID: 30662590
[TBL] [Abstract][Full Text] [Related]
12. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
13. Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome.
Harris LA; Baffy N
Postgrad Med; 2017 Nov; 129(8):872-888. PubMed ID: 28936910
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic modulation of gut microbiota: current clinical applications and future perspectives.
Ianiro G; Bibbò S; Gasbarrini A; Cammarota G
Curr Drug Targets; 2014; 15(8):762-70. PubMed ID: 24909808
[TBL] [Abstract][Full Text] [Related]
15. Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease?
Bringiotti R; Ierardi E; Lovero R; Losurdo G; Di Leo A; Principi M
World J Gastrointest Pathophysiol; 2014 Nov; 5(4):550-9. PubMed ID: 25400998
[TBL] [Abstract][Full Text] [Related]
16. Impact of Gut Microbiota Composition on Onset and Progression of Chronic Non-Communicable Diseases.
Noce A; Marrone G; Di Daniele F; Ottaviani E; Wilson Jones G; Bernini R; Romani A; Rovella V
Nutrients; 2019 May; 11(5):. PubMed ID: 31091761
[TBL] [Abstract][Full Text] [Related]
17. Beneficial Effects of Probiotics, Prebiotics, Synbiotics, and Psychobiotics in Inflammatory Bowel Disease.
Wasilewski A; Zielińska M; Storr M; Fichna J
Inflamm Bowel Dis; 2015 Jul; 21(7):1674-82. PubMed ID: 25822014
[TBL] [Abstract][Full Text] [Related]
18. Microbiota in pancreatic health and disease: the next frontier in microbiome research.
Thomas RM; Jobin C
Nat Rev Gastroenterol Hepatol; 2020 Jan; 17(1):53-64. PubMed ID: 31811279
[TBL] [Abstract][Full Text] [Related]
19. The role of the microbiome for human health: from basic science to clinical applications.
Mohajeri MH; Brummer RJM; Rastall RA; Weersma RK; Harmsen HJM; Faas M; Eggersdorfer M
Eur J Nutr; 2018 May; 57(Suppl 1):1-14. PubMed ID: 29748817
[TBL] [Abstract][Full Text] [Related]
20. Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome.
Khan I; Ullah N; Zha L; Bai Y; Khan A; Zhao T; Che T; Zhang C
Pathogens; 2019 Aug; 8(3):. PubMed ID: 31412603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
